Updated results were disclosed Wednesday night from a mid-stage clinical trial of Incyte’s epacadostat combined with Merck’s Keytruda to treat patients with metastatic melanoma.
The new data, culled from the study Incyte calls ECHO-202, look good, matching or exceeding investor expectations. Here’s a rundown:
About the Author Reprints
As a Melanoma patient who has gone through 38 rounds of IL2 in 2010 and wondering when the Melanoma would become active again in my body, well I don’t have that on my mind anymore, I found out Thursday August 31 that it’s back, I was seeking some information, doing a little research for my options.
I find it disgusting that you would withhold such vital information from the public and demand a ransom for it, I will be sure to tell everyone I know to avoid your website and cancel their subscriptions if they have one.